This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.07.029v1 50/17/1657    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toblli, J. E. Articles by Di Gennaro, F. Search for Related Content PubMed PubMed Citation Articles by Toblli, J. E. Articles by Di Gennaro, F. Related Collections Related Articles

CLINICAL RESEARCH: HEART FAILURE

Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency

Hospital Alemán, Buenos Aires, Argentina

Manuscript received March 23, 2007; revised manuscript received July 3, 2007, accepted July 8, 2007.

^_* Reprint requests and correspondence: Dr. Jorge E. Toblli, School of Medicine, University of Buenos Aires, Department of Internal Medicine, Hospital Alemán, Av. Pueyrredon 1640, Buenos Aires (1118), Argentina. (Email: jorgetoblli{at}fibertel.com.ar).

Objectives: Our objective was to evaluate in a double-blind, randomized, placebo-controlled study possible modifications in NT-pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) levels together with clinical and functional parameters, in a group of anemic patients with chronic heart failure (CHF) and chronic renal failure (CRF) receiving intravenous iron therapy, without recombinant human erythropoietin (rhEPO), versus placebo.

Background: Chronic heart failure and CRF associated with absolute or relative iron deficiency anemia is a common problem. This situation is linked with a variable inflammatory status. Both NT-proBNP and CRP are recognized markers for left ventricular dysfunction and inflammatory status, respectively. In this double-blind, randomized, placebo-controlled study, modifications in NT-proBNP and CRP level and clinical and functional parameters, in anemic patients with CHF and CRF receiving intravenous iron therapy, without rhEPO, versus placebo were evaluated.

Methods: Forty patients with hemoglobin (Hb) <12.5 g/dl, transferrin saturation <20%, ferritin <100 ng/ml, creatinine clearance (CrCl) <90 ml/min, and left ventricular ejection fraction (LVEF) 35% were randomized into 2 groups (n = 20 for each). For 5 weeks, group A received isotonic saline solution and group B received iron sucrose complex, 200 mg weekly. Minnesota Living with Heart Failure Questionnaire (MLHFQ) and 6-min walk (6MW) test were performed. NT-pro brain natriuretic peptide and CRP were evaluated throughout the study. No patients received erythroprotein any time.

Results: After 6 months follow-up, group B showed better hematology values and CrCl (p < 0.01) and lower NT-proBNP (117.5 ± 87.4 pg/ml vs. 450.9 ± 248.8 pg/ml, p < 0.01) and CRP (2.3 ± 0.8 mg/l vs. 6.5 ± 3.7 mg/l, p < 0.01). There was a correlation initially (p < 0.01) between Hb and NT-proBNP (group A: r = –0.94 and group B: r = –0.81) and after 6 months only in group A: r = –0.80. Similar correlations were observed with Hb and CRP. Left ventricular ejection fraction percentage (35.7 ± 4.7 vs. 28.8 ± 2.4), MLHFQ score, and 6MW test were all improved in group B (p < 0.01). Additionally, group B had fewer hospitalizations: 0 of 20 versus group A, 5 of 20 (p < 0.01; relative risk = 2.33).

Conclusions: Intravenous iron therapy without rhEPO substantially reduced NT-proBNP and inflammatory status in anemic patients with CHF and moderate CRF. This situation was associated with an improvement in LVEF, NYHA functional class, exercise capacity, renal function, and better quality of life.

Abbreviations and Acronyms   6MW = 6-min walk   BMI = body mass index   CHF = chronic heart failure   CRF = chronic renal failure   CRP = C-reactive protein   Hb = hemoglobin   ISC = iron sucrose complex   IV = intravenous   LV = left ventricle/ventricular   LVEF = left ventricular ejection fraction   NT-proBNP = NT-pro-brain natriuretic peptide   NYHA = New York Heart Association   rhEPO = recombinant human erythropoietin   TSAT = transferrin saturation

Related Articles

Anemia and Heart Failure: A New Pathway?

Gary S. Francis and Anne Kanderian
J. Am. Coll. Cardiol. 2007 50: 1666-1667. [Full Text] [PDF]

This article has been cited by other articles:

				P. van der Meer and D. J van Veldhuisen Anaemia and renal dysfunction in chronic heart failure Heart, November 1, 2009; 95(21): 1808 - 1812. [Full Text] [PDF]

				S. D. Anker, J. C. Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. F. Luscher, C. Mori, B. von Eisenhart Rothe, S. Pocock, et al. Rationale and design of Ferinject(R) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia Eur J Heart Fail, November 1, 2009; 11(11): 1084 - 1091. [Abstract] [Full Text] [PDF]

				A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]

				Y. Naito, T. Tsujino, M. Matsumoto, T. Sakoda, M. Ohyanagi, and T. Masuyama Adaptive response of the heart to long-term anemia induced by iron deficiency Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H585 - H593. [Abstract] [Full Text] [PDF]

				A. Kazory and E. A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 639 - 647. [Abstract] [Full Text] [PDF]

				E. D. Pagourelias, C. Koumaras, A. I. Kakafika, K. Tziomalos, P. G. Zorou, V. G. Athyros, and A. Karagiannis Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure? Angiology, February 1, 2009; 60(1): 74 - 81. [Abstract] [PDF]

				D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure Journal of Pharmacy Practice, December 1, 2008; 21(6): 420 - 423. [Abstract] [PDF]

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1671 - 1678. [Full Text] [PDF]

				H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827. [Abstract] [Full Text] [PDF]

				D. S. Silverberg, D. Wexlerb, A. Iaina, and D. Schwartz The role of correction of anaemia in patients with congestive heart failure: A short review Eur J Heart Fail, September 1, 2008; 10(9): 819 - 823. [Abstract] [Full Text] [PDF]

				I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]

				G. S. Francis and A. Kanderian Anemia and Heart Failure: A New Pathway? J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1666 - 1667. [Full Text] [PDF]